Outcomes in diabetic macular edema switched directly or after a dexamethasone implant to a fluocinolone acetonide intravitreal implant following anti-VEGF treatment

AIMS: Fluocinolone acetonide (FAc) is an intravitreal corticosteroid implant approved for the second-line treatment of diabetic macular edema (DME). This study compared outcomes of patients with DME switched directly to an FAc implant, versus indirectly via dexamethasone, after anti-VEGF therapy fai...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Acta Diabetol
Main Authors: Rehak, Matus, Busch, Catharina, Unterlauft, Jan-Darius, Jochmann, Claudia, Wiedemann, Peter
Formato: Artigo
Idioma:Inglês
Publicado: Springer Milan 2019
Assuntos:
Original Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC7093402/
https://ncbi.nlm.nih.gov/pubmed/31749051
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00592-019-01439-x
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares